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Adrenal tumors in dogs and cats 
Claudia E. Reusch 
 
Pheochromocytomas are catecholamine-producing neuroendocrine tumors arising 
from chromaffin cells of the adrenal medulla. They are considered rare in dogs and 
even more uncommon in cats.  
Pheochromocytomas are potentially malignant and local invasion into the adjacent 
vessels and other tissues is seen in more than 50% of dogs, sites of metastasis are 
regional lymph nodes, spleen, liver, kidney, pancreas, lung, heart, bone and CNS. 
The tumors are usually slow growing. Size is extremely variable and ranges between 
a few millimetres and more than 10 cm in diameter. 
Most tumors are unilateral, occasionally both adrenal glands are affected. They may 
coexist with cortisol-producing adrenocortical tumors, ACTH-producing pituitary 
tumors or other endocrine tumors.  
Clinical signs are usually the result of catecholamine excess and/or rarely from the 
space-occupying or invasive nature of the tumor. Catecholamines bind to α- and β-
adrenergic receptors and induce “fright, fight and flight” reactions. Important effects 
are: increase of heart rate and contractility, increase of blood pressure and 
respiration rate, relaxation of gastrointestinal tract and urinary bladder, increase of 
blood glucose and free fatty acids and increased alertness. In healthy dogs the 
content of the adrenal medulla is approximately 30% norepinephrine and 70% 
epinephrine. In dogs with pheochromocytoma the proportion of the hormones may be 
different from healthy dogs and norepinephrine may be the predominant secretory 
product. Hormone secretion may be constant or sporadic and is highly unpredictable. 
The disease may occur at any age, however it is most commonly seen in older dogs. 
There are no apparent sex and breed predispositions. The clinical presentation is 
highly variable. Signs may be apparent several times per day or may only reoccur 
after days, weeks or months. Severity of the disease ranges from dramatic and life-
threatening to very mild. Some pheochromocytomas are hormonally silent.  
Clinical signs may be categorized as:  
1. non-specific: anorexia, weight loss, lethargy 
2. related to the cardio-respiratory system and/or hypertension: tachypnoe, panting, 
tachycardia, arrhythmias, collapse, pale mucous membranes, nasal-, gingival-, ocular 
hemorrhage, acute blindness due to retina detachment 
3. related to the neuromuscular system: weakness, anxiety, pacing, muscle tremor, 
seizures 
4. miscellaneous: polyuria/polydipsia, vomiting, diarrhoe, painful abdomen.  
The most common signs are weakness and episodic collapse. Large tumors may 
cause abdominal distension, ascites and hind-limb edema. Intra-abdominal or 
retroperitoneal hemorrhage due to tumor rupture is also possible.  
Hypertension is one of the hallmarks of the disease. However, hypertension is not 
pathognomonic for pheochromocytoma and is also frequently found in 
hyperadrenocorticism, which is one of the most important differential diagnosis. 
Due to the episodic secretion of catecholamines hypertension is only present in 
approximately 50% of dogs by the time of examination. Typically systolic 
measurements are between 200 and 240 mm Hg, the maximum systolic blood 
pressure reported so far was 325 mm Hg. 
Often pheochromocytoma is only considered after an adrenal mass has been 
detected by ultrasonography. No pattern of echogenicity or architecture is specific for 
pheochromocytomas, other adrenal masses e.g. cortisol-producing tumors may look 
alike.  
CT and MRI  are more sensitive than ultrasonography to identify adrenal masses and 
to characterize the extent of local invasion, however they also do not allow a 
discrimination between pheochromocytoma and other adrenal masses. 
In humans, diagnosis of pheochromocytoma is mainly based on biochemical 
detection of excessive amounts of catecholamines (epinephrine, norepinephrine) and 
their metabolites (metanephrine, normetanephrine) in 24-h urine or in plasma. 
Although the question which test (urine or plasma) is best, is still somewhat 
controversial, plasma metanephrines tended to be recommended increasingly as test 
of choice. In dogs evaluation of those biomarkers for the diagnosis of 
pheochromocytoma has started only a few years ago. Since 24-hours urine sampling 
is impracticable under clinical conditions, measurements of urinary fractionated 
catecholamines and metanephrines was established in spot urine samples by 
expressing their concentrations as ratio to the urinary creatinine concentration. 
Urinary normetanephrine to creatinine ratio was shown to be the parameter, which 
differentiated dogs with pheochromocytoma best from healthy dogs and dogs with 
hypercortisolism. We are currently using a cut-off value of urinary 
normetanephrine:creatinine ratio of 4 times of normal as being diagnostic for 
pheochromocytoma. However, lower values do not exclude the disease and 
repetitive testing may therefore be required. Sample collection and urine processing 
are subject to certain conditions, such as acidification, light protection, cooled or 
frozen storage. Close collaboration with the laboratory is therefore necessary.  
A recent study investigated the performance of free normetanephrine and free 
metanephrine in plasma. Both parameters were significantly higher in dogs with 
pheochromocytoma compared to healthy dogs, dogs with adrenocortical tumours and 
dogs with non-adrenal diseases; whereas plasma free normetanephrine was the 
parameter which discriminated best. We recently compared the diagnostic 
performance of urinary and plasma catecholamines and metanephrines by evaluating 
healthy dogs and dogs with pheochromocytoma, hypercortisolism  or non-adrenal 
disease. Discrimination of dogs with pheochromocytoma was superior with urinary 
and plasma normetanephrine compared to urinary and plasma metanephrine. The 
differences between the urinary and the plasma tests were however small. In 
conclusion measurement of normetanephrine is the preferred biochemical test for 
pheochromocytoma. As differences between the urine and plasma test are minor 
decision between both tests should be made based on available technical facilities 
and dog-specific reference ranges. 
Adrenalectomy is the treatment of choice and should be performed as soon as 
possible. It has been shown that perioperative mortality decreases if dogs are 
pretreated with an α-adrenergic blocker (phenoxybenzamine) for at least 1 - 2 weeks 
before surgery. In dogs surviving the perioperative period survival for several years is 
possible.  
Primary hyperaldosteronism was first described in 1983. Since then, the disease has 
been diagnosed with increased frequency. Although no data are available concerning 
the true prevalence, it is assumed that the disease is more common than initially 
thought. This hypothesis is based on data from human medicine, where increased 
disease awareness led to a more systematic screening of the hypertensive 
population resulting in a strong increase in prevalence. Primary hyperaldosteronism 
however, seems to be very rare in dogs.  
In human medicine, 60 – 65% of patients have bilateral nodular  hyperplasia of the 
zona glomerulosa while 30 – 35% has aldosterone-producing adenomas 
(aldosteronomas). Unilateral hyperplasia and carcinomas are rare. Typical findings 
are systemic hypertension, hypokalemia and metabolic acidosis. However, because 
screening for the disease is becoming more systematic and the diagnosis is generally 
made earlier, the prevalence of hypokalemia is decreasing and nowadays the 
majority of patients are normokalemic at the time of diagnosis. Currently, 5 to 10% of 
the general hypertensive population and 20% of patients with severe or resistant 
hypertension are assumed to suffer from primary hyperaldosteronism. The degree of 
hypertension is usually moderate to severe, and patients with aldosteronoma tend to 
have higher blood pressure than patients with nodular hyperplasia. 
The consequences of increased aldosterone concentration are retention of sodium 
and water in the distal and collecting tubules of the kidneys. This results in increased 
intravascular volume and increased urinary potassium and hydrogen excretion. 
Excessive concentrations of circulating aldosterone also induce vasoconstriction and 
lead to an increase in peripheral vascular resistance. The two central mechanisms 
responsible for the development of hypertension in primary hyperaldosteronism are 
expansion of plasma and extracellular fluid volume and increase in total peripheral 
vascular resistance. Aldosterone per se has pro-inflammatory and pro-fibrotic 
properties resulting in vascular, cardiac and renal lesions. The pathophysiology of 
aldosterone-associated hypertension in cats is thought to be identical to humans.  
The majority of cats with primary hyperaldosteronism have been shown to have 
unilateral neoplasias (adenomas or carcinomas), while bilateral hyperplasia has been 
less frequently reported. Clinical signs include weakness with associated cervical 
ventroflexion, mydriasis and blindness because of hypertensive retinopathy; some 
cats also show polyuria/polydipsia. 
Almost all cats described to date have been hypokalemic at the time of diagnosis. 
However, as in human medicine, it may be possible that hyperaldosteronism is 
overlooked in cats with normal potassium levels. A more systematic screening for 
primary hyperaldosteronism may improve diagnosis and thus increase the 
prevalence of the disease. Based on data available to date, the prevalence of 
hypertension in cats with primary hyperaldosteronism appears to be high. Blood 
pressure was recorded in 30 cases, 26 of which were hypertensive. The severity 
ranged from mild to severe (185-270 mmHg), and the most common sequels were 
retinal detachment and ocular bleeding. Diagnosis requires demonstration of 
inappropriately elevated aldosterone concentration with low plasma renin activity 
(e.g. elevated aldosterone-to-renin ratio). Another test, the urinary aldosterone-to-
creatinine ratio after fludrocortisone suppression has recently been described and 
appears to be another promising diagnostic tool. The disease is often suspected only 
after the finding of an adrenal mass by ultrasonography. 
Initial treatment should be directed towards alleviation of hypertension and 
hypokalemia by using an aldosterone antagonist (spironolactone, initial dose 1-2 
mg/kg BID) and a calcium channel blocker (amlodipine besylate 0.625-1.25 mg/cat 
SID), and substituting potassium as needed. Subsequent adrenalectomy is the 
treatment of choice for animals without tumor metastasis. In the few cases described 
in the literature, as well as in the cases seen at our hospital, hypertension resolved 
after surgery. In cases in which adrenalectomy is not feasible (e.g. metastasized 
tumor, bilateral tumor or hyperplasia), medical treatment with spironolactone and 
amlodipine besylate should be continued. The two drugs combined seem to lead to 
resolution of hypertension in most cases. 
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